Recombinant virus with diminished latency and methods of using same

Patent metadata

Field	Value
Publication number	US-10166285-B2
Application number	US-51401107-A
Country	US
Kind code	B2
Filing date	Nov 9, 2007
Priority date	Nov 9, 2006
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.

First claim

We claim:

1. A recombinant virus comprising all or a portion of a herpes virus genome, wherein a latency gene or its promoter is altered or modified so that the latency gene is overexpressed or has reduced expression, wherein the latency gene is a gene that corresponds to VZV ORF29 gene and encodes a major DNA binding protein, and wherein the virus has an impaired ability to establish latency and at least one of:
the promoter is a heterologous promoter;
the latency gene is at a different location in the genome relative to its native location; or
a combination thereof.

2. The recombinant virus of claim 1 , wherein the herpes virus is selected from the group consisting of herpes simplex virus, varicella-zoster virus (VZV), Marek's disease virus, pseudorabies virus, or cytomegalovirus.

3. The recombinant virus of claim 1 , wherein the promoter is a heterologous promoter.

4. The recombinant virus of claim 1 , wherein the latency gene comprises a deletion of a nucleic acid sequence that encodes at least 10 amino acids.

5. The recombinant virus of claim 4 , wherein amino acids corresponding to amino acids 22-957 of an ORF29 having the amino acid sequence of SEQ ID NO: 3 are deleted.

6. The recombinant virus of claim 1 , wherein the latency gene is at a different location in the genome relative to its native location and comprises at least one mutation.

7. The recombinant virus of claim 1 , wherein the latency gene comprises a deletion or substitution in the nuclear localization sequence that impairs the ability of the encoded major DNA binding protein to translocate to the nucleus.

8. The recombinant virus of claim 6 , wherein the latency gene is located in a position corresponding to that between ORF65 and ORF66 of VZV.

9. The recombinant virus of claim 1 , wherein the virus is attenuated as compared to a corresponding wild type herpes virus or a reference virus.

10. An immunogenic composition comprising a recombinant virus of claim 1 and a carrier.

11. The immunogenic composition of claim 10 , further comprising an adjuvant or a live vaccine stabilizer.

12. An attenuated herpes virus having impaired latency comprising a herpes virus genome having a gene that corresponds to VZV ORF29 that has reduced expression or is overexpressed, wherein the reduced expression or overexpression of the gene corresponding to VZV ORF29 results in impaired late gene expression and the establishment of latency and wherein at least one of:
the gene corresponding to VZV ORF29 is under control of a heterologous promoter;
the gene corresponding to VZV ORF29 is at a non-native location in the herpes virus genome; or
a combination thereof.

13. The attenuated herpes virus having impaired latency of claim 12 , wherein the herpes virus is herpes simplex virus, varicella-zoster virus (VZV), Marek's disease virus, pseudorabies virus, or cytomegalovirus.

14. The attenuated herpes virus having impaired latency of claim 12 , wherein the gene corresponding to VZV ORF29 is under control of the heterologous promoter.

15. The attenuated herpes virus having impaired latency of claim 14 , wherein the heterologous promoter is from the same virus, from a different virus, or from a nonviral source.

16. The attenuated herpes virus having impaired latency of claim 14 , wherein the heterologous promoter is CMV IE promoter, Herpes simplex virus ICP4 protein promoter, or SV40 early promoter.

17. The attenuated herpes virus having impaired latency of claim 12 , wherein the gene corresponding to VZV ORF29 is at its native location.

18. The attenuated herpes virus having impaired latency of claim 12 , wherein the gene corresponding to VZV ORF29 is at a non-native location in the herpes virus genome is under control of a heterologous promoter.

19. The attenuated herpes virus having impaired latency of claim 12 , wherein the deletion in the gene corresponding to VZV ORF29 comprises a deletion corresponding to at least 10 encoded amino acids of reference sequence SEQ ID NO: 3.

20. The attenuated herpes virus having impaired latency of claim 12 , wherein the deletion in the gene corresponding to VZV ORF29 comprises a deletion corresponding to amino acids 1 to 345, amino acids 1 to 155, or amino acids 1 to 9 of reference sequence SEQ ID NO: 3.

21. An immunogenic composition comprising an effective amount of the attenuated herpes virus of claim 12 and a carrier.

22. The recombinant virus of claim 1 , wherein the latency gene is overexpressed or not expressed.

23. The attenuated herpes virus of claim 12 , wherein the gene corresponding to VZV ORF29 is overexpressed or not expressed.

Assignees

• Cohen Jeffrey I
• Pesnicak Lesley
• The Us Secretary Department Of Health & Human Services

Inventors

• Cohen Jeffrey I
• Pesnicak Lesley

Classifications

• C12N15/86

  Viral vectors · CPC title

• C12N2710/16761

  Methods of inactivation or attenuation · CPC title

• C12N2710/16734

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• C12N2710/16743

  viral genome or elements thereof as genetic vector · CPC title